Clinical Trials
36 trialsMEVPRO-1
Pfizer
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
Regeneron Pharmaceuticals
JIVAN
Aurigene Discovery Technologies Limited
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
LUTEON
Telix Pharmaceuticals (Innovations) Pty Limited
STARTRK-NG
Hoffmann-La Roche
EVER
Verity Pharmaceuticals Inc.
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo
ON-5001
OncoNano Medicine, Inc.
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Calico Life Sciences LLC
GuidePath
Novartis
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Arsenal Biosciences, Inc.
uTRACT
UroGen Pharma Ltd.
MK-6482-003
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
CheckMate 914
Bristol-Myers Squibb
The Efficacy of the IUrisure for Detection of Recurrent Urothelial Carcinoma
Wuhan Ammunition Life-tech Co., Ltd
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Altor BioScience
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Leap Therapeutics, Inc.
Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor
Endocyte
REVEAL
Nektar Therapeutics
Immunotherapy Study for Metastatic Renal Cell Cancer
Lumos Pharma
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
Acrotech Biopharma Inc.
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Celgene
STAR
SonaCare Medical
Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
Idera Pharmaceuticals, Inc.
Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned
Cellectar Biosciences, Inc.
MDX1106-01
Bristol-Myers Squibb
PROTECT-Z
AstraZeneca
Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer
BioCis Pharma Ltd
A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
AstraZeneca
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
Pharmacyclics LLC.
ATN-161 in Advanced Renal Cell Cancer
Attenuon
A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium
Eli Lilly and Company